- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 23288-49-5] Probucol
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-B0388 |
| Brand: | MCE |
| CAS: | 23288-49-5 |
Overview
| MDL | MFCD00079281 |
|---|---|
| Molecular Weight | 516.84 |
| Molecular Formula | C31H48O2S2 |
| SMILES | CC(SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1)(SC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2)C |
Summary
Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
IC50 & Target
Probucol (DH-581) is a drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. Probucol (DH-581) inhibited cholesterol efflux up to 80% in J774 macrophages expressing ABCA1. Probucol (DH-581) is an effective inhibitor of ABCA1-mediated cholesterol efflux without influencing scavenger receptor class B type I-mediated efflux. The inhibition of ABCA1 translocation to the plasma membrane may in part explain the reported in vivo high-density lipoprotein-lowering action of probucol [1] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01000467 | Korea Otsuka Pharmaceutical Co., Ltd. |
Healthy
|
February 2009 | Phase 4 |
| NCT00549978 | Korea Otsuka Pharmaceutical Co., Ltd.|Otsuka Pharmaceutical Co., Ltd. |
Healthy
|
October 2007 | Phase 4 |
| NCT02483169 | Asan Medical Center|Korea Otsuka Pharmaceutical Co., Ltd. |
Brain Ischemia|Intracranial Hemorrhages
|
June 2009 | Phase 4 |
| NCT01252056 | Otsuka Beijing Research Institute |
Diabetic Nephropathy
|
March 2010 | Phase 4 |
| NCT00655330 | Guangdong Provincial People´s Hospital |
Type 2 Diabetes Mellitus|Nephropathy
|
May 2008 | Not Applicable |
| NCT01142284 | Korea Otsuka Pharmaceutical Co., Ltd. |
Peripheral Artery Disease
|
May 19, 2010 | Phase 2 |
| NCT00426348 | Guangdong Provincial People´s Hospital |
Glomerulonephritis|IGA Nephropathy
|
May 2007 | Phase 4 |
| NCT00276133 | Yokohama City University Medical Center |
Chronic Nephropathy
|
January 2004 | Phase 4 |
| NCT01349010 | Otsuka Beijing Research Institute |
Hyperlipidemia
|
April 2011 | Phase 3 |
| NCT01291641 | Seoul National University Hospital|Korea Otsuka Pharmaceutical Co., Ltd. |
Hyperlipidemias
|
March 2011 | Phase 4 |
| NCT03753555 | General Hospital of Shenyang Military Region |
Stroke, Ischemic|Atherosclerosis, Cerebral
|
December 1, 2018 | Phase 4 |
| NCT00823849 | Otsuka Beijing Research Institute |
Type 2 Diabetes Mellitus|Arteriosclerosis Obliterans
|
October 2008 | Phase 4 |
| NCT01590901 | Otsuka Beijing Research Institute |
Healthy
|
February 2012 | Phase 1 |
| NCT00823875 | Otsuka Beijing Research Institute |
Atherosclerosis Cerebral Infarction
|
March 2009 | Phase 4 |
| NCT01013532 | Asan Medical Center|Korea Otsuka Pharmaceutical Co., Ltd. |
Brain Ischemia|Intracranial Hemorrhages
|
June 2009 | Phase 4 |
| NCT01031667 | Yonsei University|Korea Otsuka Pharmaceutical Co., Ltd. |
Therapy
|
November 2009 | Phase 4 |
| NCT02196805 | Otsuka Beijing Research Institute |
Chinese Healthy Volunteers
|
March 2009 | Not Applicable |
| NCT02707458 | Douglas Mental Health University Institute|Weston Brain Institute|McGill University |
Dementia of the Alzheimer Type|Age-related Cognitive Decline|Mild Cognitive Impairment Due to Alzheimer Disease
|
April 2016 | Phase 1|Phase 2 |
| NCT01726816 | Korea Otsuka Pharmaceutical Co., Ltd. |
Diabetic Nephropathy
|
October 2012 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 193.48 mM )
H 2 O : 0.67 mg/mL ( 1.30 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.9348 mL | 9.6742 mL | 19.3483 mL |
| 5 mM | 0.3870 mL | 1.9348 mL | 3.8697 mL |
| 10 mM | 0.1935 mL | 0.9674 mL | 1.9348 mL |
References
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.